Endpoints 11 winner 2025: Lila Sciences will let ‘scientific superintelligence’ run the labnews2025-09-19T14:00:05+00:00September 19th, 2025|Endpoints News|
Shape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2Bnews2025-09-18T13:45:49+00:00September 18th, 2025|Endpoints News|
Life sciences VC firm, with Bob Langer as chair, closes $77M inaugural fundnews2025-09-18T12:00:28+00:00September 18th, 2025|Endpoints News|
ArsenalBio, a well-funded cell therapy startup, halves workforce to focus resourcesnews2025-09-18T02:55:31+00:00September 18th, 2025|Endpoints News|
Joe Jimenez’s new biotech inks up to $1B biobuck deal for Mabwell’s cardio siRNAnews2025-09-17T13:32:58+00:00September 17th, 2025|Endpoints News|
Affini-T CEO appears to have left startup, raising questions about company’s shutdownnews2025-09-17T12:18:28+00:00September 17th, 2025|Endpoints News|
Ollin lands $100M to test eye drugs from Chinese partners and bring in more assetsnews2025-09-17T10:30:15+00:00September 17th, 2025|Endpoints News|
Dualitas gets $65M in Series A to develop bispecifics for immunologynews2025-09-16T11:00:54+00:00September 16th, 2025|Endpoints News|
Former CinCor executives launch Juca Bio and AllRock Bio for PAHnews2025-09-16T11:00:23+00:00September 16th, 2025|Endpoints News|
Odyssey gets $213M Series D after backing out of IPOnews2025-09-10T12:00:00+00:00September 10th, 2025|Endpoints News|
